Novartis cuts top commercial title - replaces departing exec Marie-France Tschudin with AbbVie vet Patrick Horber.
#pharma #PharmaceuticalIndustry #PharmaceuticalCompanies #Novartis #AbbVie
#abbvie #novartis #pharmaceuticalcompanies #pharmaceuticalindustry #pharma
[Automatic repost https://twitter.com/dystobot/status/1650623203419602944]
RT @UNMCPMR: Day 2 of Botox training with #abbvie. UNMC PM
FDA rejects Teva’s high-potency biosimilar of Humira again — After a record run, fewer biotechs are going public— Sarepta shares drop as report says FDA almost rejected under-review gene therapy -- See more on our front page news http://bit.ly/w28kSd #tevapharma #fda #humira #abbvie #biosimilars #ipos #genetherapy #sarepta #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#tevapharma #FdA #humira #abbvie #biosimilars #ipos #genetherapy #sarepta #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Q1 claimed the highest number of trial starts in 2022 — AbbVie knocks down earnings forecast due to IPR&D charge — FDA forces unproven premature birth drug Makena off market -- See more on our front page news http://bit.ly/w28kSd #abbvie #researchanddevelopment #fda #makena #pretermbirth #clinicaltrials #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#abbvie #researchanddevelopment #FdA #makena #PretermBirth #clinicaltrials #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
AbbVie clinches back-to-back clinical wins in ulcerative colitis, lupus — Biotech startups face ‘Series A cliff’ as venture capital stays cautious— Incyte hit by CRL on extended-release JAK tablets -- See more on our front page news http://bit.ly/w28kSd #abbvie #ulcerativecolitis #lupus #startups #funding #venturecapital #seriesa #seriesb #fda #completeresponseletter #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#abbvie #ulcerativecolitis #lupus #Startups #funding #VentureCapital #seriesa #SeriesB #FdA #completeresponseletter #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#Abbvie worst company help ever..
Worst help ever.. 4 people, CREON assistance.. never got copy of my application, how do I give that to my doctor to ok? Fail. System broken, untrained help, no one knows how to help me..
AbbVie's Humira, 5 Pfizer drugs among those with price hikes that exceeded inflation rate — Amgen is sued for concealing $10.7 billion tax bill from investors— In his first year as Johnson & Johnson CEO, Duato scored $13.1M payout -- See more on our front page news http://bit.ly/w28kSd #abbvie #pfizer #humira #drugpricing #inflation #taxes #amgen #legal #jnj #executivepay #ceos #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#abbvie #pfizer #humira #drugpricing #inflation #taxes #amgen #legal #jnj #executivepay #ceos #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
AbbVie CEO Gonzalez scored $26M in 2022 pay as cash cow Humira neared patent cliff— What ancient art form has inspired many technological advances for medical devices? — FDA delays review of BioMarin's hemophilia gene therapy after data update-- See more on our front page news http://bit.ly/w28kSd #abbvie #pharmaceos #patents #devices #meddevice #medtech #productdesign #hemophilia #biomarin #genetherapy #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#abbvie #pharmaceos #patents #devices #MedDevice #medtech #productdesign #hemophilia #biomarin #genetherapy #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
GSK and Novartis report earnings — Amgen adopts a two-price strategy for first Humira biosimilar, Amjevita — Legislative hurdles anticipated for biopharma in 2023 -- See more on our front page news http://bit.ly/w28kSd #gsk #novartis #earnings #amgen #humira #abbvie #biosimilar #drugpricing #legislation #biopharma #biotech #biotechnology #pharma #pharmanews #cafepharma
#gsk #novartis #earnings #amgen #humira #abbvie #biosimilar #drugpricing #Legislation #biopharma #biotech #biotechnology #pharma #pharmanews #cafepharma
#AbbVie for years delayed competition for its blockbuster drug #Humira, at the expense of patients and taxpayers. The monopoly is about to end.
https://www.nytimes.com/2023/01/28/business/humira-abbvie-monopoly.html
Amgen, navigating 'industry headwinds,' puts 300 commercial jobs on chopping block — The end of the Humira era — Biotech pipeline hosts 163 potential meds for mental illness, with depression dominating -- See more on our front page news http://bit.ly/w28kSd #amgen #layoffs #humira #biosimilars #abbvie #biotech #pipeline #mentalhealth #mentalillness #depression #pharma #pharmanews #biotechnology #biopharma #cafepharma
#amgen #layoffs #humira #biosimilars #abbvie #biotech #pipeline #mentalhealth #mentalillness #depression #pharma #pharmanews #biotechnology #biopharma #cafepharma
I'm NOT saying the executives of #AbbVie should have all their money taken away from them, dragged from their gilded mansions, and placed in stocks in the town square for people to throw rotten vegetables at...
But I wouldn't shed a tear if that happened. https://www.seattletimes.com/business/how-a-drug-company-made-114-billion-by-gaming-the-u-s-patent-system/?utm_source=RSS&utm_medium=Referral&utm_campaign=RSS_seattle-news
How a #Drug Company Made $114 Billion by Gaming the US #Patent System
Over the past 20 years, #AbbVie and its former parent company increased #Humira’s price about 30 times, most recently by 8% this month over 60% total to over $80,000 a year!
https://nyti.ms/3HAC7Lr #healthcar
#drug #patent #abbvie #humira #healthcar
O AbbVie, you used the patent law
To keep competition at a draw
Your monopoly was sad
But now, it's time to be glad
As competition comes to restore us all
#abbvie #humira #patentsystem #monopoly #ode #poetry
https://www.nytimes.com/2023/01/28/business/humira-abbvie-monopoly.html
#humira #abbvie #monopoly #patentsystem #ode #poetry
📢 Calling all early-career biomedical researchers!
🔹 We are excited to announce our Call for Applications for our new BioMed X Institute in New Haven, CT.
🔹 The new project - a collaboration with AbbVie - will focus on developing Complex Human Ex Vivo Models of Tissue Inflammation.
🔹Want to know more? Register for our #webinar: https://us02web.zoom.us/webinar/register/WN_3bT9ztlyQOGBW6oMYn3H_Q
🔹Don't miss this chance, apply now: https://career.bio.mx/call/2023-NHV-C01
#BioMedX #AbbVie #Medicine #Yale #NewHaven #CT #USA #CellCulture #immunology
#Webinar #biomedx #abbvie #medicine #yale #newhaven #ct #usa #cellCulture #immunology
Looking past Humira, AbbVie boosts sales forecasts for successor drugs — JPM23, Day 3: Takeda relishing in-person meetups — AstraZeneca and Avillion win approval for new asthma rescue treatment in adults -- See more on our front page news http://bit.ly/w28kSd #jpm2023 #jpm23 #humira #abbvie #takeda #asthma #astrazeneca #fda #biotech #biotechnology #biopharma #pharma #pharmanews #cafepharma
#jpm2023 #jpm23 #humira #abbvie #takeda #Asthma #astrazeneca #FdA #biotech #biotechnology #biopharma #pharma #pharmanews #cafepharma
AZ wins patent fight with Viatris, gains more exclusivity for blockbuster Symbicort — AbbVie leaves PhRMA, BIO: reports —Astellas’ Phase III gastric cancer therapy trial meets primary endpoint -- See more on our front page news http://bit.ly/w28kSd #astrazeneca #patents #Symbicort #BIO #PhRMA #abbvie #astellas #clinicaltrials #gastriccancer #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma
#astrazeneca #patents #symbicort #bio #phrma #abbvie #astellas #clinicaltrials #gastriccancer #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma
Talk about the tail wagging the dog: #AbbVie is leaving both PhRMA and BIO because "there was...frustration that AbbVie’s vigorous patent battles could spill over and damage the industry’s overall image." Man, when the trade orgs won't go to bat for you 🤣
https://www.statnews.com/2022/12/15/abbvie-exits-major-pharmaceutical-industry-lobbying-groups
Amgen to buy Horizon in biotech's biggest deal of 2022 — AbbVie slapped with age discrimination lawsuit, following other pharmas — ASH 2022: Brisol Myers, Roche, Gracell, Bluebird Bio, and more -- See more on our front page news http://bit.ly/w28kSd #amgen #horizontherapeutics #mergersandacquisitions #agediscrimination #abbvie #legal #lawsuits #ash22 #bristolmyerssquibb #bluebirdbio #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma
#amgen #horizontherapeutics #mergersandacquisitions #agediscrimination #abbvie #legal #lawsuits #ash22 #bristolmyerssquibb #bluebirdbio #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma
Merck buying out blood cancer biotech Imago for $1.4B — Teva taps former Sandoz head Francis as next CEO —AbbVie's blood cancer bispecific gets FDA priority review -- See more on our front page news http://bit.ly/w28kSd #merck #bloodcancer #mergersandacquisitions #ceos #tevapharm #abbvie #bispecificantibodies #fda #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#merck #bloodcancer #mergersandacquisitions #ceos #tevapharm #abbvie #bispecificantibodies #FdA #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma